XIENCE V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study (XIENCE V USA Long Term Follow-up Cohort).

Trial Profile

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study (XIENCE V USA Long Term Follow-up Cohort).

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jul 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms XVU-LTF
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 13 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 16 Oct 2011 Planned end date changed from 1 Mar 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 09 May 2011 Planned end date changed from 1 Jan 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top